Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.
Animals
Calcium Channel Blockers
/ administration & dosage
Calcium Channels
/ metabolism
Drug Therapy, Combination
Female
Imidazoles
/ administration & dosage
Myelin Sheath
/ drug effects
Nerve Degeneration
/ etiology
Optic Nerve
/ surgery
Optic Nerve Injuries
/ complications
Piperazines
/ administration & dosage
Quinoxalines
/ administration & dosage
Rats
Receptors, AMPA
/ antagonists & inhibitors
Receptors, Purinergic P2X7
/ metabolism
Rosaniline Dyes
/ administration & dosage
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 10 2019
25 10 2019
Historique:
received:
19
07
2019
accepted:
07
10
2019
entrez:
27
10
2019
pubmed:
28
10
2019
medline:
6
11
2020
Statut:
epublish
Résumé
Injury to the central nervous system is exacerbated by secondary degeneration. Previous research has shown that a combination of orally and locally administered ion channel inhibitors following partial optic nerve injury protects the myelin sheath and preserves function in the ventral optic nerve, vulnerable to secondary degeneration. However, local administration is often not clinically appropriate. This study aimed to compare the efficacy of systemic and local delivery of the ion channel inhibitor combination of lomerizine, brilliant blue G (BBG) and YM872, which inhibits voltage-gated calcium channels, P2X
Identifiants
pubmed: 31653948
doi: 10.1038/s41598-019-51886-3
pii: 10.1038/s41598-019-51886-3
pmc: PMC6814709
doi:
Substances chimiques
Calcium Channel Blockers
0
Calcium Channels
0
Imidazoles
0
Piperazines
0
Quinoxalines
0
Receptors, AMPA
0
Receptors, Purinergic P2X7
0
Rosaniline Dyes
0
YM 872
11G3FV7PG7
lomerizine
DEE37CY4VO
coomassie Brilliant Blue
M1ZRX790SI
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
15297Références
Neuroscience. 1994 Nov;63(1):135-49
pubmed: 7898644
Ann Clin Transl Neurol. 2015 Jul;2(7):711-21
pubmed: 26273684
Neurobiol Aging. 2012 Aug;33(8):1816-28
pubmed: 22048123
J Neurosci. 2018 Jul 18;38(29):6491-6504
pubmed: 29915135
Glia. 2010 Apr 15;58(6):730-40
pubmed: 20029962
J Physiol. 2016 Jan 1;594(1):39-57
pubmed: 26365250
J Biol Chem. 1993 Apr 15;268(11):8199-203
pubmed: 8463330
CNS Drug Rev. 2002 Winter;8(4):337-52
pubmed: 12481190
J Pharmacol Toxicol Methods. 1998 Jul;40(1):1-12
pubmed: 9920528
Exp Neurol. 2014 Nov;261:136-46
pubmed: 24931225
Front Cell Neurosci. 2017 Jan 13;10:310
pubmed: 28133446
J Pharmacol Exp Ther. 1998 Nov;287(2):559-66
pubmed: 9808681
J Neurotrauma. 2011 Jun;28(6):1077-88
pubmed: 21381867
Eur J Neurol. 2009 Oct;16(10):1112-7
pubmed: 19469828
J Neurotrauma. 2010 Feb;27(2):439-52
pubmed: 19852581
J Anat. 2007 Jun;210(6):693-702
pubmed: 17504270
Acta Pharmacol Sin. 2009 Apr;30(4):379-87
pubmed: 19343058
J Concussion. 2017 Jan-Dec;1:
pubmed: 30828466
J Neurosurg. 1996 Dec;85(6):1113-21
pubmed: 8929504
J Neurosci. 2007 Aug 29;27(35):9525-33
pubmed: 17728465
J Vis Exp. 2010 Aug 16;(42):
pubmed: 20736920
J Neurochem. 1973 Oct;21(4):759-73
pubmed: 4754856
Prog Brain Res. 2002;137:171-6
pubmed: 12440367
J Am Assoc Lab Anim Sci. 2011 Sep;50(5):600-13
pubmed: 22330705
Anesth Analg. 1993 Jul;77(1):141-8
pubmed: 8317722
J Neuroinflammation. 2018 Jul 7;15(1):201
pubmed: 29981582
Neurotherapeutics. 2010 Jan;7(1):100-14
pubmed: 20129502
Neuroscience. 2016 Dec 17;339:450-462
pubmed: 27725216
Neuropharmacology. 2013 Dec;75:380-90
pubmed: 23958451
J Neurosci Res. 1995 Jun 1;41(2):213-21
pubmed: 7650757
Acta Neurochir Suppl. 2003;86:305-7
pubmed: 14753458
BMC Neurosci. 2017 Aug 14;18(1):62
pubmed: 28806920
Med Mycol. 2010 Mar;48(2):430-5
pubmed: 20141377
Invest Ophthalmol Vis Sci. 2005 Mar;46(3):884-90
pubmed: 15728544
Neuroscience. 2001;103(4):873-83
pubmed: 11301198
Exp Brain Res. 2019 Jan;237(1):161-171
pubmed: 30367192
Exp Neurol. 2009 Mar;216(1):219-30
pubmed: 19118550
Sci Rep. 2016 Mar 04;6:22595
pubmed: 26940762
Eur J Neurosci. 2007 Jan;25(1):231-8
pubmed: 17241284
Acta Neurochir (Wien). 1992;115(3-4):106-11
pubmed: 1605077
PLoS One. 2013 Jun 19;8(6):e66448
pubmed: 23840470
J Neurotrauma. 2002 Apr;19(4):427-38
pubmed: 11990349
Drug Deliv. 2015 May;22(3):243-57
pubmed: 24471801
Med Hypothesis Discov Innov Ophthalmol. 2013 Summer;2(2):41-6
pubmed: 24600641
Stroke. 2001 May;32(5):1208-15
pubmed: 11340235
Neural Regen Res. 2014 Mar 15;9(6):565-74
pubmed: 25206855
Bio Protoc. 2018 Dec 20;8(24):e3118
pubmed: 34532560
ACS Chem Neurosci. 2011 Nov 16;2(11):645-57
pubmed: 22860159
Acta Med Okayama. 2005 Aug;59(4):121-7
pubmed: 16155637
Cardiovasc Psychiatry Neurol. 2011;2011:765923
pubmed: 21436875
Brain Res. 2003 Nov 21;991(1-2):104-12
pubmed: 14575882
Neural Regen Res. 2014 Jun 1;9(11):1096-9
pubmed: 25206765
Invest Ophthalmol Vis Sci. 2003 Aug;44(8):3388-93
pubmed: 12882786
Toxicology. 2013 Sep 6;311(1-2):69-77
pubmed: 23583883
Mol Neurobiol. 2008 Oct;38(2):123-8
pubmed: 18704769
J Pharm Pharmacol. 2005 Feb;57(2):177-81
pubmed: 15720780
J Neurosci Res. 2002 Nov 15;70(4):588-98
pubmed: 12404513
Clin Exp Pharmacol Physiol. 1999 Nov;26(11):870-6
pubmed: 10561807